PRECLINICAL PHARMACOKINETIC EVALUATION OF VALSARTAN FLOATING TABLETS FORMULATED USING CROSS LINKED STARCH UREA - A NEW MODIFIED STARCH

Swathi G¹, K. P. R. Chowdary² and A. Muralidhar Rao.³
¹Maheshwara Institute of Pharmacy, Hyderabad- 502307.
²Research Director, Vikas Institute of Pharmaceutical sciences, Rajahmundry-533102.
³S N Vanitha Pharmacy Maha Vidhyalaya, Hyderabad-500001.

Received: 02 March 2017
Accepted: 10 March 2017
Published: 28 March 2017

Abstract:
The objective of the present study is optimization of valsartan floating tablet formulation by 2³ factorial design and to evaluate the optimized valsartan floating tablets for in vitro drug release, preclinical pharmacokinetics and also for in vivo correlation (IVIVC). Valsartan is an orally active anti-hypertensive drug, majorly absorbed from stomach and upper small intestine. Formulation of sustained release floating tablets of valsartan is needed because of its poor oral bioavailability and short biological half-life. Valsartan floating tablets were formulated as per 2³ factorial design and were evaluated. Valsartan floating tablets prepared as per 2³ factorial design were non-disintegrating in water and aqueous acidic (pH 1.2) and alkaline (pH 7.4) fluids and were of good quality with regard to drug content, hardness, friability and suitable for controlled release. Formulations Fa, Fab, Fabc exhibited excellent floating over >12 h with a floating lag time in the range 12-40 seconds. Higher levels (20 %) of sodium bicarbonate gave shorter floating lag time. Valsartan release from the floating tablets prepared except formulation Fa, was slow and spread over 12 h and dependent on the composition of the tablets. Drug release from formulation Fa was very rapid. Valsartan release from the floating tablets was by non-fickian diffusion mechanism in all the cases except Fa. In the case of formulation Fa that gave rapid release of drug fickian diffusion was the drug release mechanism. Optimization of valsartan floating tablet formulation was done taking floating lag time as the parameter for optimization. For optimization, floating lag time was taken as response (Y) and level of sodium bicarbonate as (X₁), level of beeswax as (X₂) and level of starch acetate as (X₃).

The polynomial equation describing the relationship between the response, Y and the variables, X₁, X₂ and X₃ based on the observed data was found to be Y = 8.996 - 8.596 (X₁) + 2.396 (X₂) – 2.431 (X₁ X₂) + 0.561 (X₃) - 0.521 (X₁ X₃) + 0.396 (X₂ X₃) - 0.271 (X₁ X₂ X₃).

Based on the polynomial equation developed, the optimized valsartan floating tablet formulation with a floating lag time of 20 seconds could be formulated employing sodium bicarbonate (160mg/tablet), beeswax (28mg/tablet) and starch acetate (10mg/tablet). The optimized formulation (Fo) exhibited a floating time of 12-14 h with a lag time of 21 seconds fulfilling the target floating lag time set indicating validity of the optimization technique employed. Formulations Fa and Fab prepared exhibited excellent floating characteristics (floating over 12 h with a lag time of 21 and 12 seconds respectively) and good sustained release of valsartan over 12–14h. The optimized valsartan tablets formulated at two strengths 80 mg/tablet and 40 mg/tablet gave slow, gradual and complete release of valsartan in 12h. Valsartan was absorbed rapidly from IR tablets and slowly over longer period of time from floating tablets. Based on (AUC)₁₀α, the relative bioavailability (BA) of Valsartan from FTs was 166.0 % when compared to Valsartan IR tablets (100%). A good level A correlation (r = 0.961) was observed between percent drug released (in vitro) and (AUC)₁₀α (in vivo).

Key words: Cross Linked starch Urea, Floating tablets, Valsartan, Optimization, Preclinical, Pharmacokinetics.

Corresponding Author:
Prof K.P.R Chowdary,
Research Director,
Vikas Institute of Pharmaceutical sciences,
Rajahmundry-533102.
Mobile No: 9866283578
Email address: prof.kprchowdary@rediffmail.com

Please cite this article in press K.P.R Chowdary et al. Preclinical Pharmacokinetic Evaluation of Valsartan Floating Tablets Formualted Using Cross Linked Starch Urea - A New Modified Starch, Indo Am. J. P. Sci, 2017; 4(03).
INTRODUCTION:
Oral drug delivery is the most desirable and preferred method of administering therapeutic agents for their systemic effects. The high level of patient compliance in taking oral dosage forms is due to the ease of administration, patient compliance, flexibility in formulation and handling of these forms[1]. However the oral route of administration suffers with certain limitations such as short residence time of the dosage form in the gastrointestinal tract, unpredictable gastric emptying, degradation of the drug due to highly reactive nature of gastrointestinal contents and existence of an absorption window in the gastric and upper small intestine for several drugs. Gastric emptying is a complex process and makes in vivo performance of the drug delivery system uncertain. Formulation of floating drug delivery systems is a useful approach to avoid this variability with increased gastric retention time of the drug delivery system. Floating systems or hydrodynamically controlled systems are low-density systems that have sufficient buoyancy to float over the gastric contents and remain buoyant in the stomach for a prolonged period of time. While the system is floating on the gastric contents, the drug is released slowly at the desired rate from the system. After release of drug, the residual system is emptied from the stomach. This results in an increased gastric residence time and a better control of the fluctuation in plasma drug concentration [2], [3]. Several approaches are currently used to retain the dosage in the stomach. These include bioadhesive systems, swelling and expanding systems, floating systems and other delayed gastric emptying devices [4], [5].

The principle of floating tablets offers a simple and practical approach to achieve increased residence time in the stomach and upper gastrointestinal tract to enhance the bioavailability and to obtain controlled release. Floating tablets are designed based on gas generating principle. Design of floating tablets needs a strong matrix forming polymer, a gas generating agent and a floating enhancer such as beeswax.

In the present study sustained release floating tablets of valsartan were formulated employing Cross linked starch-urea, a new modified starch (50 %) as matrix forming polymer, sodium bicarbonate as gas generating agent and beeswax and starch acetate as floating enhancers. Valsartan is an angiotensin receptor blocker widely prescribed for hypertension. It is absorbed from stomach and upper small intestine [6], [7]. The oral bioavailability of valsartan was 23 %. It has a short biological half-life of 3-6 hrs [8]. Hence sustained release floating tablet formulation is needed for valsartan to enhance its oral bioavailability and to prolong its therapeutic effect, to reduce dosage frequency and to increase patient compliance.

Floating tablets of valsartan were designed in the present study to enhance its bioavailability and to achieve sustained release over 12 h for b.i.d. administration. Sustained release of valsartan over 12h is aimed in addition to good floating characteristics. Formulation of valsartan floating tablets was optimized [9] by 2 factorial designs. The objective of the present study is optimization of valsartan floating tablet formulation by 2 factorial design and to evaluate the optimized valsartan floating tablets for in vitro drug release, preclinical pharmacokinetics and also for in vitro – in vivo correlation (IVIVC).

MATERIALS AND METHODS:
Materials
Valsartan was a gift sample from M/s Micro Labs Ltd, Pondicherry. Cross linked starch-urea was prepared in the laboratory. Starch acetate (50 cps), sodium bicarbonate, Lactose and beeswax were procured from commercial sources. All other materials used were of Pharmacopoeial grade.

Methods
Preparation of Cross linked Starch - Urea Polymer [10]
Potato starch (9 parts) was dispersed in purified water (10 parts) to form starch slurry. Urea (1 part), calcium chloride (1 part) were dissolved in purified water (40 parts) and the solution was heated to boiling. While boiling, the starch slurry was added and mixed. Mixing while heating was continued for 20 minutes to form cross-linked starch-urea polymer. The mass formed was spread on to a stainless steel plate and dried at 85°C for 6-8 h. The dried polymer was powdered and passed through mesh No. 120.

Formulation of Floating Tablets
Matrix tablets each containing 80 mg of valsartan were formulated employing Cross linked starch- urea (50%) as matrix forming polymer, sodium bicarbonate as gas generating agent and starch acetate and beeswax as floating enhancers. Valsartan floating tablets were formulated as per 2 factorial design. The three factors involved in the 2 factorial design are sodium bicarbonate (Factor A), beeswax (Factor B) and starch acetate (Factor C). The two levels of sodium bicarbonate (Factor A) are 10 % and 20 %, the two levels of beeswax (Factor B) are 2 % and 5 % and the two levels of starch acetate (Factor C) are 5% and 10%. Eight valsartan floating tablet formulations were prepared employing selected combinations of the levels of the three factors as per 2 factorial design. The floating tablets were prepared by melting- wet granulation method as per the formula given in Table 1.
Table 1: Formulae of Valsartan Floating Tablets
Prepared as Per 2³ Factorial Design and Optimized Formulation

| Ingredient (mg/tab) | F (1) | F (a) | F (b) | F (ab) | F (c) | F (ac) | F (bc) | F (abc) | F (opt) |
|---------------------|-------|-------|-------|--------|-------|--------|--------|---------|--------|
| Valsartan           | 80    | 80    | 80    | 80     | 80    | 80     | 80     | 80      | 80     |
| Sodium bicarbonate  | 80    | 160   | 80    | 160    | 80    | 160    | 80     | 160     | 160    |
| Beeswax             | 16    | 16    | 40    | 40     | 16    | 16     | 40     | 40      | 28     |
| Starch acetate      | 40    | 40    | 40    | 40     | 80    | 80     | 80     | 80      | 10     |
| Crosslinked starch Urea | 400   | 400   | 400   | 400    | 400   | 400    | 400    | 400     | 400    |
| Lactose             | 164   | 84    | 140   | 60     | 124   | 44     | 100    | 20      | 102    |
| Talc                | 10    | 10    | 10    | 10     | 10    | 10     | 10     | 10      | 10     |
| Magnesium stearate  | 10    | 10    | 10    | 10     | 10    | 10     | 10     | 10      | 10     |
| Total weight (mg)   | 800   | 800   | 800   | 800    | 800   | 800    | 800    | 800     | 800    |

The required quantities of valsartan, Cross linked starch-urea, starch acetate, lactose and sodium bicarbonate were thoroughly mixed in a dry mortar by following geometric dilution technique. Beeswax was melted in a dry beaker and the blend of the above mentioned ingredients was added to the molten beeswax and mixed thoroughly. The blend was transferred to a dry mortar and granulated with hydro-alcoholic (1:1) solution. The dried granules formed were passed through mesh No. 16 to break the aggregates. The lubricants talc and magnesium stearate were passed through mesh No. 60 on to the dry granules and blended in a closed polyethylene bag. The tablet granules were then compressed into 800mg tablets on a 8-station tablet punching machine (Karnavathi Rimek Minipress II) to a hardness of 4-5 Kg/cm².

Evaluation of Tablets
Hardness of the tablets was tested using a Monsanto hardness tester. Friability of the tablets was determined in a Roche friabilitator. Disintegration time of the tablets was determined using a Paramount tablet disintegration test machine using water, 0.1N HCl and phosphate buffer of pH 7.4 as the test fluids.

Estimation of Valsartan
An ultraviolet (UV) spectrophotometric method based on the measurement of absorbance at 250 nm in 0.1N HCl was used for the estimation of valsartan. The method obeyed Beer-Lambert’s law in the concentration range of 0-10 μg / mL. When a standard drug solution was assayed repeatedly (n=6), the relative error (accuracy) and coefficient of variation (precision) were found to be 0.75% and 1.45% respectively. No interference from the excipients used was observed.

Floating Lag Time and Floating Time
In Vitro buoyancy was determined by measuring floating lag time and duration of floating. The tablets were placed in a 250 ml glass beaker containing 0.1N HCl. The time required for the tablet to rise to the surface and float was determined as floating lag time. The duration in which the tablet remains floating was determined as floating time.

Drug Release Study
Drug release from the floating tablets prepared was studied using 8-station dissolution rate test apparatus (Labindia, DS 8000) employing a paddle stirrer at 50 rpm and at a temperature of 37±1°C. Hydrocholoric acid, 0.1 N (900 mL) was used as dissolution fluid. A 5mL aliquot of dissolution medium was withdrawn through a filter (0.45μm) at different time intervals and assayed spectrophotometrically by measuring absorbance at 250 nm. All drug release experiments were conducted in triplicate (n=3).
Data Analysis
Drug release data were analysed as per Zero order, first order, Higuchi and Korsemeyer - Peppas equation models to assess drug release kinetics and mechanism from the floating tablets prepared.

Preclinical Pharmacokinetic Evaluation:

*In vivo* Pharmacokinetic evaluation was done on optimized Valsartan Floating Tablets in comparison to its immediate release (IR) tablets in normal healthy rabbits of either sex with a view to evaluate their *in vivo* performance.

**In vivo study protocol:**
The following products were tested for *in vivo* pharmacokinetic evaluation

(i) Valsartan (40mg) IR tablets and

(ii) Optimized Valsartan FT (40mg)

As Valsartan studied is safe and for ease of its determination in plasma samples by HPLC, the products are tested in rabbits at human doses after approved by IAEC. Institutional Animal Ethics Committee (No. CPCSEA/CH/ORG/2015-040) approved the protocols. The *in vivo* study was conducted as per crossover RBD (n=6) in each case. Healthy rabbits weighing 2.0 -2.5 Kg were used. The washout period was one month .After collecting the blank blood sample, the product in the study was administered orally with 10 ml of water. Blood samples (1.0 ml) were collected from marginal ear vein at different times (0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11and 12h) after administration. Samples were collected into heparinized test tubes and were centrifuged for 15 min at 15,000 rpm. The plasma samples were stored under refrigerated conditions at 4-8°C prior to assay for drug content on the same day. The plasma concentrations of valsartan were determined by a reported HPLC method [13] after revalidation.

Estimation of Pharmacokinetic Parameters:

Assuming one compartment open model, various Pharmacokinetic parameters such as C_{max}, T_{max} (AUC)_{(0-12h)}, (AUC)_{(0-∞)}, K_{el}, t_{1/2} and K_{a} were estimated from the Plasma drug concentration data in each case. Standard known methods [14], [15] were used for the estimation of various pharmacokinetic parameters.

**RESULTS AND DISCUSSION:**

The principle of floating tablets offers a simple and practical approach to achieve increased residence time in the stomach and upper G.I. tract to enhance the bioavailability and to obtain controlled release. Floating tablets of valsartan were designed based on gas generating principle. The objective of the present study is formulation development and optimization of valsartan floating tablets based on gas generating principle.

Matrix tablets each containing 80 mg of valsartan were formulated employing Cross linked starch- urea (50%) as matrix forming polymer, sodium bicarbonate as gas generating agent and starch acetate and beeswax as floating enhancers. Valsartan floating tablets were formulated as per 2³ factorial design. The three factors involved in the 2³ factorial study are sodium bicarbonate (Factor A), beeswax (Factor B) and starch acetate (Factor C). The two levels of sodium bicarbonate (Factor A) are 10 % and 20 %, the two levels of beeswax (Factor B) are 2 % and 5 % and the two levels of starch acetate (Factor C) are 5% and 10%. Eight valsartan floating tablet formulations were prepared employing selected combinations of the levels of the three factors as per 2³ factorial design. The floating tablets were prepared by melting- wet granulation method as per the formula given in Table 1. All the floating tablets prepared were evaluated for drug content, hardness, friability, disintegration time, floating lag time, floating time and drug release characteristics.

The physical parameters of the floating tablets prepared are given in Table 2.

| Table 2: Physical Parameters of Valsartan Floating Tablets  
Prepared as per 2³ Factorial Design and Optimized Formulation |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Formulation     | Hardness (Kg/cm²) | Friability (% wt. loss) | Drug Content (mg/tablet) | Floating lag time (min- sec) | Floating Time (h) |
| F₁              | 4.5              | 0.65             | 79.60              | 12-30              | >12             |
| Fₐ              | 5.5              | 0.45             | 80.05              | 0-40               | >12             |
| Fₐ              | 5.0              | 0.58             | 80.25              | 20-40              | >12             |
| Fₐ                | 4.5              | 0.30             | 80.15              | 0-12               | >12             |
| Fₐ              | 5.5              | 0.45             | 79.20              | 13-20              | >12             |
| Fₐ              | 5.5              | 0.48             | 79.45              | 0-30               | >12             |
| Fₐ              | 5.0              | 0.72             | 79.80              | 24-10              | >12             |
| Fₐ              | 4.5              | 0.45             | 80.20              | 0-32               | >12             |
| Fₐ              | 5.5              | 0.60             | 80.15              | 0-21               | >12             |
Hardness of the tablets was in the range 4.5-5.5 Kg/cm². Weight loss in the friability test was in the range of 0.35 % – 0.72 % in all the cases. All the tablets prepared contained valsartan within 100±2% of the labelled claim. All the floating tablets prepared were found to be non-disintegrating in water and aqueous acidic (pH 1.2) and alkaline (pH 7.4) fluids. As such the prepared floating tablets were of good quality with regard to drug content, hardness, friability and were suitable for controlled release.

In the in vitro buoyancy study, the floating lag time of various tablets was in the range 12 seconds to 24.17 minutes. Floating time of all the tablets prepared was more than 12 hours. The floating lag time values were subjected to ANOVA to find out the significance of the individual and combined effects of the three factors, sodium bicarbonate, beeswax and starch acetate on the floating characteristics of the tablets prepared. The results of ANOVA indicated that the individual effects of sodium bicarbonate (Factor A) and starch acetate (Factor C) and their combined effect (AC) on the floating lag time are significant (P < 0.05). Whereas the individual effect of bees wax (Factor B) and all other combined effects of the three factors involved are not significant in influencing floating lag time of the tablets.

The order of increasing floating lag time observed with various floating tablets prepared was \( F_{ab} < F_{ac} < F_{abc} < F_1 < F_c < F_b < F_{bc} \). Formulations \( F_a, F_{ab}, F_{ac} \) and \( F_{abc} \) exhibited excellent floating over 12-14 h with a floating lag time in the range 12-40 seconds. Sodium bicarbonate at 20 % strength gave less floating lag time than at 10 % strength. Formulations \( F_a, F_{ab}, F_{ac} \) and \( F_{abc} \) are considered as the best floating tablets formulated based on the floating characteristics.

Valsartan release from the floating tablets formulated was studied in 0.1 N hydrochloric acid. Drug release parameters of the tablets prepared are summarized in Table 4. Valsartan release from the floating tablets prepared was slow and spread over 12 - 14 h and depended on the composition of the tablets. The release data were analyzed as per zero order, first order, Higuchi and Korsemeyer- Peppas kinetic models. The correlation coefficient (r) values in the analysis of release data as per different kinetic models are given in Table 3. The drug release plots are shown in Figs 1 – 2.

Drug release from all the floating tablets prepared was diffusion controlled as indicated by the linear Higuchi plots. When the release data were analyzed as per Korsemeyer- Peppas equation, the release exponent ‘n’ was found to be in the range 0.51 - 0.63 in all the cases except formulation \( F_a \) indicating ‘non-Fickian diffusion’ as the release mechanism from these floating tablets. In the case of formulation \( Fa \), that gave rapid release of drug, the release exponent ‘n’ was found to be 0.10 indicating fickian diffusion as the drug release mechanism.

### Table 3: Correlation Coefficient (r) values in the analysis of Release data of Floating Tablets of Valsartan as per various Kinetic models

| Formulation | Zero Order | First Order | Higuchi | Korsemeyer - Peppas |
|-------------|------------|-------------|---------|---------------------|
| \( F_1 \)   | 0.9272     | 0.9726      | 0.9978  | 0.9955              |
| \( F_a \)   | 0.492      | 0.9808      | 0.9878  | 0.9818              |
| \( F_b \)   | 0.9582     | 0.9612      | 0.9936  | 0.9928              |
| \( F_{ab} \)| 0.9497     | 0.9673      | 0.9978  | 0.9978              |
| \( F_c \)   | 0.9328     | 0.9837      | 0.9928  | 0.9879              |
| \( F_{ac} \)| 0.9793     | 0.9758      | 0.9810  | 0.9898              |
| \( F_{bc} \)| 0.9558     | 0.9873      | 0.9923  | 0.9905              |
| \( F_{abc} \)| 0.9570     | 0.9487      | 0.9869  | 0.9792              |
| \( F_{opt} \)| 0.9609     | 0.9407      | 0.9932  | 0.9964              |
Optimization:

Optimization of valsartan floating tablet formulation was done taking floating lag time as the parameter for optimization. For optimization, floating lag time was taken as response (Y) and level of sodium bicarbonate as (X₁), level of bees wax as (X₂) and level of starch acetate as (X₃). The polynomial equation describing the relationship between the response, Y and the variables, X₁, X₂ and X₃ based on the observed data was found to be

\[ Y = 8.996 - 8.596 (X_1) + 2.396 (X_2) - 2.431 (X_1 X_2) + 0.561 (X_3) - 0.521 (X_1 X_3) + 0.396 (X_2 X_3) - 0.271 (X_1 X_2 X_3). \]

The magnitude of the coefficients of the variables in the polynomial equation indicates the relative strength of the variables in influencing the response involved. In the above polynomial equation, the coefficients of variables X₁ (sodium bicarbonate) is much higher when compared to the coefficients of other variables. As such the results indicate that the floating lag time is much influenced by the sodium bicarbonate levels in the formulation.
Based on the above polynomial equation, the optimized valsartan floating tablet formulation with a floating lag time of 20 seconds or 0.33 min could be formulated employing sodium bicarbonate (160 mg/tablet), beeswax (28 mg/tablet) and starch acetate (10 mg/tablet). To verify valsartan floating tablets were formulated employing the optimized levels of sodium bicarbonate, beeswax and starch acetate as per the formula given in Table 1. The optimized valsartan floating tablet formulation was prepared and evaluated for floating and drug release characteristics. The optimized formulation exhibited a floating time of 14 h with a lag time of 21 seconds fulfilling the target floating lag time set. This result also indicated validity of the optimization technique employed. The optimized valsartan tablets were formulated at two strengths 80 mg/tablet and 40 mg/tablet. Both the optimized valsartan tablets formulated gave slow, gradual and complete release of valsartan in 12 h. Floating tablets containing 40 mg of valsartan per tablet were used in pharmacokinetic studies.

**Preclinical pharmacokinetic evaluation:**

Plasma concentrations of Valsartan observed following the oral administration of valsartan IR tablets and Floating tablets are shown in Fig: 3

The pharmacokinetic parameters estimated are summarized in Table 5. The $K_{el}$ and $t_{1/2}$ were 0.304 h$^{-1}$ and 2.278 h respectively for Valsartan IR tablets and 0.168 h$^{-1}$ and 4.112 h respectively for Valsartan FTs. The $t_{1/2}$ of Valsartan estimated is in good agreement with the reported [8] value of 3-6 h.

Valsartan was absorbed rapidly from IR tablets with an absorption rate constant $(K_a)$ of 2.00 h$^{-1}$. A $C_{max}$ of 7.5 ± 0.19 µg/ml was observed at 2 h following oral administration of Valsartan IR tablets. Plasma concentration were later decreased rapidly.

![Fig. 3: Plasma Concentration Vs. Time Profile of Valsartan IR and FTs in Rabbits (n=6)](image)

| Pharmacokinetic Parameter | Valsartan (IR) Tablets | Valsartan (FTS) Tablets |
|---------------------------|------------------------|------------------------|
| $C_{max}$ (µg/ml)         | 7.5±0.19               | 7.0±0.09               |
| $T_{max}$ (h)             | 2.0                    | 3.0                    |
| $K_a$ (h$^{-1}$)          | 0.304                  | 0.168                  |
| $t_{1/2}$ (h)             | 2.278                  | 4.112                  |
| $AUC_{0}^{12}$ (µg.h/ml)  | 31.10                  | 44.90                  |
| $AUC_{0}^{n}$ (µg.h/ml)   | 32.02                  | 53.23                  |
| $K_e$ (h$^{-1}$)          | 2.00                   | 0.963                  |
| Rel BA (%)               | 100                    | 166.0                  |
Valsartan from the FTs was absorbed slowly with a $K_a$ of 0.963 h$^{-1}$; a $C_{max}$ of 7.0 ± 0.09µg/ml at 3 h was observed with FTs. The plasma drug concentrations were sustained within a narrow range for extended period of time in the case of FTs.

Based on $(AUC)_{O,α}$, the relative bioavailability (BA) of Valsartan from FTs was 166.0% when compared to Valsartan IR tablets (100%).

A good level A correlation ($r = 0.961$) was observed between percent drug released (in vitro) and $(AUC)_{O,α}$ (in vivo) as shown in Fig 4.

Thus, the results of pharmacokinetic studies indicated that Valsartan was absorbed slowly from FTs and the plasma drug concentrations were sustained over longer period of time when compared to IR tablets. FTs also exhibited higher bioavailability when compared to IR tablets.

**CONCLUSIONS:**

1. Valsartan floating tablets prepared as per $2^3$ factorial design were non-disintegrating in water and aqueous acidic (pH 1.2) and alkaline (pH 7.4) fluids and were of good quality with regard to drug content, hardness, friability and suitable for controlled release.

2. Formulations Fa, Fab, Fwa, and Fabc exhibited excellent floating over >12 h with a floating lag time in the range 12-40 seconds. Higher levels (20%) of sodium bicarbonate gave shorter floating lag time.

3. Valsartan release from the floating tablets prepared except formulation Fa was slow and spread over 12 h and dependent on the composition of the tablets. Drug release from formulation Fa was very rapid.

4. Valsartan release from the floating tablets was by non-fickian diffusion mechanism in all the cases except Fa. In the case of formulation Fa that gave rapid release of drug fickian diffusion was the drug release mechanism.

5. Optimization of valsartan floating tablet formulation was done taking floating lag time as the parameter for optimization. For optimization, floating lag time was taken as response (Y) and level of sodium bicarbonate as ($X_1$), level of bees wax as ($X_2$) and level of starch acetate as ($X_3$).

6. The polynomial equation describing the relationship between the response, Y and the variables, $X_1$, $X_2$ and $X_3$ based on the observed data was found to be $Y = 8.996 - 8.596 (X_1) + 2.396 (X_2) - 2.431 (X_1 X_2) + 0.561 (X_3) - 0.521 (X_1 X_3) + 0.396 (X_2 X_3) - 0.271 (X_1 X_2 X_3)$.

7. Based on the polynomial equation developed, the optimized valsartan floating tablet formulation with a floating lag time of 20 seconds could be formulated employing sodium bicarbonate (160mg/tablet), beeswax (28mg/tablet) and starch acetate (10mg/tablet).

8. The optimized formulation ($F_{opt}$) exhibited a floating time of 12-14 h with a lag time of 21 seconds fulfilling the target floating lag time set indicating validity of the optimization technique employed.

9. Formulations $F_{opt}$ and Fab prepared exhibited excellent floating characteristics (floating over 12 h with a lag time of 21 and 12 seconds respectively) and good sustained release of valsartan over 12-14 h.

10. The optimized valsartan tablets formulated at two strengths 80 mg/tablet and 40 mg/tablet gave slow, gradual and complete release of valsartan in 12 h.
Valsartan was absorbed rapidly from IR tablets and slowly over longer period of time from floating tablets.

Based on \( \text{AUC}_o \), the relative bioavailability (BA) of Valsartan from FTs was 166.0% when compared to Valsartan IR tablets (100%).

A good level A correlation \( (r = 0.961) \) was observed between percent drug released \( \text{(in vitro)} \) and \( \text{AUC}_o \) \( \text{(in vivo)} \).

**REFERENCES:**

1. Ansel HC, Allen LV, Popovich NG. Pharmaceutical Dosage Forms and Drug Delivery systems. Philadelphia, Lippincott Williams and Wilkins Chapter -3, 2003, 23-31.
2. Amit K. N, Ruma M, and Biswarup D, Gastroretentive drug delivery systems: a review, Asian Journal of Pharmaceutical and Clinical Research, 2010, 3,(1), 2-10.
3. Mayavanshi AV, Gajar SS. Floating drug delivery system to increase gastric retention of drug: A Review, J. Pharm. Res., 1940:345-348, 2008.
4. Moes A.J, Gastroretentive dosage forms critical review, Therapeutic Drug Carrier System, 199310, 143-95.
5. Fell J. T, Whitehead L, and Collet J.H, “Prolonged gastric retention using floating dosage forms”, Pharmaceutical Technology, 2000, 24, 82-90.
6. Nadeem Siddiqui, Asif Husain, Lakshita Chaudhry, M Shamsher Alam, Moloy Mitra and Parminder S.Bhasin, Pharmacological and Pharmaceutical Profile of Valsartan: A Review, Journal of Applied Pharmaceutical Science 2011;01 (04):12-19.
7. Sandina Swetha, Ravi Teja Allena and Gowda D V, A Comprehensive Review on Gastroretentive Drug Delivery Systems, International Journal of Research in Pharmaceutical and Biomedical Science, 2012 ;3 (3):1285-1293.
8. Zaid A N, Cortesi R, Qaddomi A, Khammassh S, Formulation and Bioequivalence of Two Valsartan Tablets after a single oral Administration, Sci Pharm, 2011,79,123-135.
9. Bolton S, Pharmaceutical Statistics, New York, NY, Marcel Decker Inc, 2nd Edition, 1990, 532-570.
10. Swathi G, Chowdary K. P. R. And Muralidhar Rao A, Formulation and evaluation of captopril floating tablets employing a new modified starch – optimization by \( 2^3 \) factorial design, World Journal of Pharmaceutical Research ,2015, 4(10), 946-958.
11. Higuichi, T, Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices, J. Pharm. Sci., 1963, 52: 1145-9.
12. Korsmeyer RW, Gurny R, Doelkar E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers, Int. J. Pharm.,1983, 15, 25-35.
13. Milena Pérez, Gloria Ramírez, Mauricio Pérez, Piedad Restrepo, Validation of an analytical method for the determination of Valsartan in human plasma by HPLC/UV with addition standard using Losartan as an internal standard, Colombia Médica, 2007, 38, (1), 13-20.
14. Wagner, J. G. and Nelson, E., Per cent absorbed time plots derived from blood level and/or urinary excretion data, J. Pharm. Sci., 1963, 52, 610.
15. Wagner, J. G. and Nelson, E., kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug, J. Pharm. Sci., 1964, 53, 1392.